Ultragenyx Pharmaceutical Inc.
RAREFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
560
Cost of Revenue
77
Gross Profit
484
Gross Margin
86.3%
Operating Income
-536
Operating Margin
-95.7%
Net Income
-569
Net Margin
-101.6%
EPS (Basic)
$-6.29
EPS (Diluted)
$-6.29
EBITDA
-469
EBITDA Margin
-83.7%
2023
12/31/2023
Revenue
434
Cost of Revenue
45
Gross Profit
389
Gross Margin
89.6%
Operating Income
-569
Operating Margin
-131.1%
Net Income
-607
Net Margin
-139.7%
EPS (Basic)
$-8.25
EPS (Diluted)
$-8.25
EBITDA
-516
EBITDA Margin
-118.9%
2022
12/31/2022
Revenue
363
Cost of Revenue
28
Gross Profit
335
Gross Margin
92.2%
Operating Income
-649
Operating Margin
-178.6%
Net Income
-707
Net Margin
-194.7%
EPS (Basic)
$-10.12
EPS (Diluted)
$-10.12
EBITDA
-640
EBITDA Margin
-176.3%
2021
12/31/2021
Revenue
351
Cost of Revenue
16
Gross Profit
335
Gross Margin
95.4%
Operating Income
-382
Operating Margin
-108.6%
Net Income
-454
Net Margin
-129.2%
EPS (Basic)
$-6.70
EPS (Diluted)
$-6.70
EBITDA
-410
EBITDA Margin
-116.8%
2020
12/31/2020
Revenue
271
Cost of Revenue
6
Gross Profit
265
Gross Margin
97.7%
Operating Income
-330
Operating Margin
-121.8%
Net Income
-187
Net Margin
-68.8%
EPS (Basic)
$-3.07
EPS (Diluted)
$-3.07
EBITDA
-140
EBITDA Margin
-51.6%